Drug Trial Radar · NCT06112379
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,902
Actual
Start
Nov 14, 2023
Primary completion
Nov 20, 2028
Study completion Sep 23, 2032
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.
Conditions
- Breast Cancer
Interventions
Dato-DXdDrug
Experimental drug IV infusion
DurvalumabDrug
Experimental drug IV Infusion
PembrolizumabDrug
IV Infusion Active comparator
DoxorubicinDrug
IV infusion Experimental/Active Comparator
EpirubicinDrug
IV Infusion Experimental/Active Comparator
CyclophosphamideDrug
IV infusion Experimental/Active Comparator
PaclitaxelDrug
IV infusion Experimental/Active Comparator
CarboplatinDrug
IV infusion Experimental/Active Comparator
CapecitabineDrug
Tablet Oral route of administration Experimental/Active Comparator
OlaparibDrug
Tablet Oral route of administration Experimental/Active Comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS) in the experimental vs control armsTime frame: Date of randomization to date of the EFS event, up to 93 months after the first subject randomized
Locations
283 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Daphne, Alabama
Research Site
Prescott, Arizona
Research Site
Jonesboro, Arkansas
Research Site
Rogers, Arkansas
Research Site
Los Angeles, California
Research Site
Santa Barbara, California
Research Site
Santa Rosa, California
Research Site
Torrance, California
Research Site
Aurora, Colorado
Research Site
Longmont, Colorado
Research Site
Bridgeport, Connecticut
Research Site
New Haven, Connecticut
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
St. Petersburg, Florida
Research Site
West Palm Beach, Florida
Research Site
Atlanta, Georgia
Research Site
Des Moines, Iowa
Research Site
Edgewood, Kentucky
Research Site
Louisville, Kentucky
Research Site
Baton Rouge, Louisiana
Research Site
Annapolis, Maryland
Research Site
Boston, Massachusetts
Research Site
Grand Rapids, Michigan
Research Site
Traverse City, Michigan
Research Site
Burnsville, Minnesota
Research Site
Minneapolis, Minnesota
Research Site
Columbia, Missouri
Research Site
Omaha, Nebraska
Research Site
East Brunswick, New Jersey
Research Site
New Brunswick, New Jersey
Research Site
Santa Fe, New Mexico
Research Site
New York, New York
Research Site
Charlotte, North Carolina
Research Site
Durham, North Carolina
Research Site
Winston-Salem, North Carolina
Research Site
Blue Ash, Ohio
Research Site
Eugene, Oregon
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Showing 40 of 283 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.